---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-019999"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:29:19.603733+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience reports record Q2 revenue $75.3M (+25% YoY), raises FY2024 guidance

## Summary
- Record revenue $75.3M (+25% YoY); orders $93.2M (+45% YoY).
- Net loss $45.5M ($0.79/sh) vs $59.2M ($1.04) YoY; adjusted EBITDA -$26.8M.
- Gross margin improved to 41% from 31%; FY2024 revenue guidance raised to $300-304M, gross margin 41.5-42.0%.
- Cash burn improved: net cash from ops -$42.4M H1FY24 vs -$98.4M; cash $293.3M.
- NGS revenue $40.8M (+41% YoY), SynBio $29.8M (+23%), Biopharma $4.7M (-33%).

## SEC filing metadata
- accession: 0001628280-24-019999
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000162828024019999/0001628280-24-019999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000162828024019999/twist-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-019999
- JSON: https://secwatch.observer/filing/0001628280-24-019999.json
- Plain text: https://secwatch.observer/filing/0001628280-24-019999.txt

## Key facts
- Earnings Releases
  Twist Bioscience Corp reported fiscal year 2024 results: revenue $300M to $304M. Guidance raised.
  - Period: fiscal year 2024
  - Revenue: $300M to $304M
  - Guidance: raised
  - Result: guidance update
  source text: — Increased FY 2024 revenue guidance to a range of $300M to $304M; Increased FY 2024 gross margin guidance to a range of 41.5 to 42.0% —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1581280/000162828024019999/0001628280-24-019999-index.htm
- Earnings Releases
  Twist Bioscience Corp reported fiscal second quarter ended March 31, 2024 results: revenue $75.3 million, net income -$45.5 million, EPS -$0.79.
  - Period: fiscal second quarter ended March 31, 2024
  - Revenue: $75.3 million
  - Net income: -$45.5 million
  - EPS: -$0.79
  - Result: reported results
  source text: FISCAL 2024 SECOND QUARTER FINANCIAL RESULTS • Orders: Total orders received for the second quarter of fiscal 2024 increased to $93.2 million compared to $64.2 million for the same period of fiscal 2023 . • Revenue: Total revenues for the second quarter of fiscal 2024 increased to $75.3 million compared to $60.2 million for the same period of fiscal 2023 . ◦ SynBio revenue increased to $29.8 million for the second quarter of fiscal 2024 compared to $24.2 million for the same period of fiscal 2023. ◦ NGS revenue increased to $40.8 million for the second quarter of fiscal 2024 compared to $29.0 million for the same period of fiscal 2023. ◦ Biopharma revenue was $4.7 million for the second quarter of fiscal 2024 compared to $7.0 million in the same period of fiscal 2023. • Cost of Revenues: Cost of revenues for the second quarter of fiscal 2024 was $44.4 million compared to $41.7 million for the same period of fiscal 2023 . • Gross Margin: Gross margin for the second quarter of fiscal 202
  evidence_url: https://www.sec.gov/Archives/edgar/data/1581280/000162828024019999/0001628280-24-019999-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.